Profile data is unavailable for this security.
About the company
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
- Revenue in EUR (TTM)304.10m
- Net income in EUR320.66k
- Incorporated1988
- Employees426.00
- LocationPharming Group NVDarwinweg 24LEIDEN 2333 CRNetherlandsNLD
- Phone+31 715247400
- Fax+31 715247445
- Websitehttps://www.pharming.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Corona Remedies Ltd | 124.27m | 15.85m | 925.05m | 4.57k | 58.38 | -- | 47.87 | 7.44 | 28.01 | 28.01 | 219.70 | -- | -- | -- | -- | 2,980,876.00 | -- | -- | -- | -- | 81.28 | -- | 12.75 | -- | -- | 55.10 | -- | -- | 17.93 | -- | 65.11 | -- | -- | -- |
| Wuhan Keqian Biology Co Ltd | 122.97m | 55.72m | 926.84m | 924.00 | 16.74 | 1.83 | -- | 7.54 | 0.9796 | 0.9796 | 2.16 | 8.95 | 0.2209 | 2.86 | 3.23 | 1,097,706.00 | 9.97 | 11.71 | 11.17 | 13.56 | 65.26 | 73.57 | 45.16 | 44.51 | 5.02 | -- | 0.0017 | 32.23 | -11.48 | 13.17 | -3.43 | 9.52 | -4.93 | -- |
| SSY Group Ltd | 492.05m | 70.77m | 934.14m | 5.70k | 13.45 | 1.22 | 7.74 | 1.90 | 0.223 | 0.223 | 1.55 | 2.46 | 0.3616 | 2.27 | 2.11 | 751,065.60 | 5.27 | 9.41 | 6.34 | 12.43 | 42.68 | 56.47 | 14.58 | 17.65 | 2.40 | 14.91 | 0.346 | 42.91 | -10.67 | 4.49 | -19.53 | -1.36 | -8.36 | 9.73 |
| Lushang Freda Pharmaceutical Co Ltd | 457.91m | 25.96m | 934.25m | 3.63k | 35.90 | 1.84 | -- | 2.04 | 0.2112 | 0.2112 | 3.72 | 4.12 | 0.633 | 3.37 | 7.63 | 1,040,448.00 | 4.45 | 0.7994 | 6.29 | 5.29 | 51.41 | 23.96 | 7.02 | 3.71 | 3.96 | -- | 0.0393 | 43.21 | -13.02 | -17.29 | -19.73 | -6.70 | 21.16 | 0.00 |
| Pharming Group NV | 304.10m | 320.66k | 957.97m | 426.00 | 399.77 | 4.28 | 72.33 | 3.15 | 0.0034 | 0.0034 | 0.4792 | 0.3189 | 0.8057 | 0.5655 | 7.89 | 713,849.90 | 0.0156 | 2.22 | 0.0191 | 2.68 | 89.90 | 89.40 | 0.0193 | 3.88 | 2.39 | 3.14 | 0.331 | -- | 21.15 | 9.46 | -12.26 | -- | -49.98 | -- |
| Cisen Pharmaceutical Co Ltd | 432.00m | 59.75m | 960.63m | 3.30k | 16.14 | 1.29 | -- | 2.22 | 1.08 | 1.08 | 7.84 | 13.59 | 0.472 | 2.10 | 5.34 | 1,079,074.00 | 6.58 | 6.51 | 8.12 | 8.07 | 53.70 | 55.92 | 13.94 | 10.84 | 3.48 | -- | 0.0069 | 37.16 | -10.77 | -0.6464 | -2.38 | -0.2215 | -0.3051 | 10.42 |
| Polypeptide Group AG | 370.35m | -34.70m | 962.64m | 1.37k | -- | 2.90 | -- | 2.60 | -0.9512 | -0.9512 | 10.11 | 9.15 | 0.5153 | 2.06 | 6.35 | 261,878.90 | -4.83 | 0.555 | -6.57 | 0.7099 | 11.63 | 19.25 | -9.37 | 1.05 | 0.8234 | -0.1909 | 0.2517 | 62.37 | 4.28 | 10.70 | 61.97 | -- | 34.57 | -- |
| Heilongjiang ZBD Pharmaceutical Co Ltd | 193.49m | -40.33m | 962.91m | 2.35k | -- | 1.09 | -- | 4.98 | -0.3545 | -0.3545 | 1.70 | 7.75 | 0.1303 | 0.6358 | 0.4977 | 679,399.90 | -2.74 | 3.29 | -3.80 | 4.46 | 44.16 | 37.24 | -21.03 | 10.59 | 1.33 | -1.45 | 0.3114 | 24.43 | -13.90 | -3.87 | -7.30 | 1.41 | 1.13 | -7.12 |
| Xeris Biopharma Holdings Inc | 223.37m | -13.13m | 969.26m | 394.00 | -- | -- | -- | 4.34 | -0.1033 | -0.1033 | 1.67 | -0.0052 | 0.77 | 0.7301 | 5.61 | 675,474.60 | -4.52 | -31.61 | -6.46 | -42.28 | 84.56 | 79.76 | -5.88 | -77.77 | 1.35 | 0.3853 | 1.00 | -- | 23.89 | 136.89 | 11.92 | -- | -4.75 | -- |
| EyePoint Inc | 35.54m | -172.69m | 977.64m | 165.00 | -- | 4.89 | -- | 27.51 | -2.99 | -2.99 | 0.617 | 2.88 | 0.1532 | 1.02 | 59.51 | 256,606.10 | -74.47 | -35.88 | -86.87 | -42.05 | 94.08 | 84.82 | -485.95 | -201.78 | 7.11 | -- | 0.00 | -- | -5.97 | 16.27 | -84.86 | -- | 80.24 | -- |
| China Animal Husbandry Industry Co., Ltd | 761.54m | 26.00m | 981.79m | 4.30k | 37.76 | 1.42 | -- | 1.29 | 0.21 | 0.21 | 6.15 | 5.60 | 0.6863 | 5.30 | 4.19 | 1,461,064.00 | 2.32 | 5.25 | 3.37 | 7.48 | 15.59 | 22.15 | 3.38 | 7.31 | 1.62 | -- | 0.1625 | 31.16 | 11.30 | 7.79 | -82.41 | -22.24 | -0.0699 | -21.83 |
| Zhejiang Ausun Pharmaceutical Co Ltd | 91.07m | 22.41m | 991.58m | 1.22k | 43.95 | 3.48 | -- | 10.89 | 0.2241 | 0.2241 | 0.8963 | 2.83 | 0.2472 | 0.9248 | 3.00 | 616,180.10 | 6.08 | 8.91 | 7.77 | 12.10 | 51.51 | 53.44 | 24.61 | 27.68 | 2.17 | -- | 0.1383 | 27.35 | -2.63 | 20.90 | -18.55 | 29.68 | 17.53 | 43.79 |
Data as of Feb 10 2026. Currency figures normalised to Pharming Group NV's reporting currency: Euro EUR
12.89%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Norges Bank Investment Managementas of 02 Feb 2026 | 22.23m | 3.24% |
| Acadian Asset Management LLCas of 09 Jan 2026 | 21.46m | 3.13% |
| BlackRock Fund Advisorsas of 28 Jan 2026 | 15.66m | 2.29% |
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 7.85m | 1.15% |
| DWS Investment GmbHas of 03 Feb 2026 | 6.96m | 1.02% |
| BlackRock Advisors (UK) Ltd.as of 28 Jan 2026 | 2.96m | 0.43% |
| Deka Investment GmbHas of 08 Jan 2026 | 2.89m | 0.42% |
| Lazard Asset Management LLCas of 31 Jan 2026 | 2.80m | 0.41% |
| Parametric SASas of 14 Jan 2025 | 2.79m | 0.41% |
| Nordea Investment Management ABas of 31 Dec 2025 | 2.74m | 0.40% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
